Search

News Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A

Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis published last year assessed its efficacy and safety in patients previously treated for hemophilia A.

Source: Hemophilia 14. 4. 2022

News 6 Years Follow-Up of Patients with Breast Cancer in the APHINITY Study

The primary analysis of results from the APHINITY clinical trial supported the combined anti-HER2 treatment with trastuzumab and pertuzumab in combination with chemotherapy in patients with early HER2-positive breast cancer. At the end of last year, efficacy and safety results of this treatment after more than 6 years of follow-up were presented.

Source: Breast Carcinoma 17. 4. 2020

News Biochemotherapy of Aggressive Rectal Carcinoma –⁠ A Case Study from the Czech Republic

Colorectal cancer arises from a complex interplay of environmental and lifestyle factors complemented by hereditary factors. Nowadays, it represents not only a health concern but also a socioeconomic problem. It is the second most common malignant tumor in both sexes; fortunately, its incidence and mortality have been decreasing in recent years. Due to expanding and more accurately targeted treatment options and good patient care management, it is also possible to better manage more aggressive and previously difficult-to-treat forms of the disease, as demonstrated by the following case study from the Comprehensive Cancer Center of the University Hospital Hradec Králové.

Source: Colorectal Cancer 7. 12. 2022

News Safe Long-term Treatment of Nasal Symptoms in Patients with Perennial Allergic Rhinitis

In persistent allergic rhinitis, achieving symptom control is often difficult despite pharmacological treatment and minimizing contact with the allergen. Good efficacy in clinical studies has been shown with combined therapy of intranasal antihistamines with locally acting corticosteroids. The presented study evaluated the long-term safety profile and efficacy of a fixed combination of olopatadine with mometasone.

Source: Life Without Allergic Rhinitis 24. 3. 2022

News Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction

The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure or death from cardiovascular (CV) causes in the EMPEROR-Reduced study in patients with adequately treated heart failure with reduced left ventricular ejection fraction (HFrEF) compared to placebo, regardless of whether the patients had diabetes. A post hoc analysis of this study focused on another important question: how does the benefit of adding empagliflozin interact with the standard disease-modifying therapy for heart failure?

Source: Heart Failure 5. 8. 2022

News Erlotinib in Conditions of Routine Clinical Practice

The patient population in clinical trials is always somewhat selected. Only a well-conducted analysis of real-world clinical practice data can provide a clearer picture of the efficacy and safety of a drug. Therefore, we are currently witnessing a significant development in this type of clinical research, for example, in the form of nationwide cohort studies. How did erlotinib perform in one of them for the treatment of non-small cell lung cancer?

Source: Oncological Treatment 18. 5. 2022

News Risk Factors and Therapy of Chronic Leg Ulcers Lasting More Than 6 Months

The therapy of chronic leg ulcers in diabetics continues to be a significant challenge for attending physicians and surgeons. Authors of a recently published study have addressed the risk factors, clinical symptoms, and, last but not least, the therapy outcomes of chronic leg ulcers lasting more than 6 months.

Source: Wound Healing 3. 2. 2020

News Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?

Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and North America. However, this field is experiencing very dynamic developments, both in terms of diagnosis and therapy. The biggest changes have occurred in treatment regimens, and recommendations for the therapy of relapsed or refractory CLL have also changed. Innovations have also emerged in prognostic examinations. As part of the update to the 'Red Book' by the Czech Hematological Society ČLS JEP (CHS), fresh recommendations concerning this disease were published in October 2023.

Source: Chronic Lymphocytic Leukemia 7. 12. 2023

News Lung screening in the Czech Republic has detected over a hundred cases of lung cancer

The purpose of lung screening, which has been ongoing in the Czech Republic since January 2022, is to detect early stages of lung cancer and increase awareness of this malignant disease in relation to smoking. Data analysis from health insurance companies through the National Registry of Paid Health Services (NRHZS) revealed that out of nearly 4,000 individuals who underwent low-dose CT as part of the screening examination, 116 were diagnosed with cancer.

Source: Respiratory Health 7. 12. 2023

News Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results

A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer products with an extended elimination half-life.

Source: Hemophilia 8. 8. 2022

News Benefits and Cost-Effectiveness of Superabsorbent Dressings in the Treatment of Venous Leg Ulcers

A recent cost-effectiveness analysis based on German data showed that using superabsorbent dressings instead of conventional dressings in the treatment of venous leg ulcers with moderate to high exudation increases the likelihood of healing, quality of life, and reduces direct healthcare costs. Similar results were found in another analysis from last year, this time using French data, comparing superabsorbent dressings with foam dressings, again in the treatment of venous leg ulcers.

Source: Wound Healing 26. 4. 2023

News Register of Patients Treated with Growth Hormone (REPAR): Data Analysis as a Path to Further Optimization of Care

Treatment with recombinant growth hormone (rhGH) is available in the Czech Republic for all children meeting the indication criteria. A network of 10 centers covers the entire country, and all doctors authorized to prescribe growth hormone are united in the Pediatric Growth Hormone Working Group. The Czech national Register of Patients Treated with Growth Hormone (REPAR) has been collecting data on patients treated with rhGH since 2014. The aim of the presented work was to analyze selected data and present the basic demographics of patients included in this database during the first 5 years of its existence.

Source: Growth Disorders 30. 11. 2020

News Impact of Candesartan on Achieving Remission in Patients with Active IgA Nephropathy

IgA nephropathy is the most common glomerulonephritis worldwide and in the Czech Republic. The effect of candesartan (an angiotensin receptor blocker) on the remission of active IgA nephropathy in patients treated with steroid pulses and tonsillectomy was investigated by the randomized study presented below.

Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5

One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized patients with COVID-19 infection during the period of predominant omicron variants including subvariants BA.4 and BA.5 has provided real-world data confirming the position of this antiviral in the first line of treatment for patients with mild to moderately severe SARS-CoV-2 infection and a high risk of severe disease.

Source: COVID-19 16. 10. 2023

News Pharmacokinetics of Concentrates for the Treatment of von Willebrand’s Disease

Von Willebrand's disease (vWD) is characterized by a deficiency or reduced functional capacity of von Willebrand factor (vWF) and, in more severe cases, by a deficiency of coagulation factor VIII (FVIII). Treatment usually requires repeated infusions of vWF and FVIII concentrate, with available products having different factor ratios. Repeated infusions of concentrates can lead to different FVIII exposures when using different products. The pharmacokinetics of two products with varying vWF and FVIII ratios have been compared in experimental preclinical and clinical studies.

Source: Von Willebrand Disease 14. 11. 2022